3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Melanoma
7
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Neoplasms
6
Lymphoma, Non-Hodgkin
6
Carcinoma, Non-Small-Cell Lung
6
Uterine Cervical Neoplasms
4
Prostatic Neoplasms
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Lymphoma
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Carcinoma, Merkel Cell
4
Triple Negative Breast Neoplasms
3
Stomach Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Neoplasm Metastasis
3
Multiple Myeloma
3
Head and Neck Neoplasms
3
Carcinoma, Transitional Cell
3
Small Cell Lung Carcinoma
2
Skin Neoplasms
2
Lymphoma, Follicular
2
Lymphoma, B-Cell
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Hematologic Neoplasms
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Interventions
pembrolizumab
6
Proton Therapy
3
spartalizumab
2
Rosuvastatin Calcium
2
Paclitaxel
2
Immune Checkpoint Inhibitors
2
Cetuximab
2
toripalimab
1
sotorasib
1
peposertib
1
osimertinib
1
necitumumab
1
mirdametinib
1
leronlimab
1
apatinib
1
amivantamab
1
abemaciclib
1
Valganciclovir
1
Trastuzumab
1
Therapeutics
1
Rifampin
1
Radiotherapy
1
PankoMab-GEX
1
Panitumumab
1
Midazolam
1
Metformin
1
MEK inhibitor I
1
Jupiter
1
JPT1 protein, human
1
Itraconazole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Solid Tumor, Adult
×
Interleukin-2
×
Clear all
NCT05307874
2025-12-24
EVICTION-2
ImCheck Therapeutics
Phase 1/2
Completed
56 enrolled